Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Takeda continues post-Shire selloff to the benefit of Korean biopharma Celltrion, says GlobalData

South Korea-based bio/pharma company Celltrion has recently agreed to acquire a portfolio of 18 prescription pharmaceutical products and over-the-counter medicines across the Asia-Pacific (APAC) region for US$278.3m from Japan-based drug giant Takeda. This acquisition by Celltrion is part of Takeda’s massive divestment program to help release it from its crippling debt from its recent US$62bn […]
Read more

As Trump and Biden push to ‘Buy American’, $354m Government award to manufacture COVID-19 medicines in US raises suitability questions, says GlobalData

The US Federal Government’s Biomedical Advanced Research and Development Authority (BARDA) award of $354m to Phlow Corporation for the manufacture of COVID-19 medicines and other essential drugs has been touted by the Trump Administration as bringing pharmaceutical manufacturing back to the US. However, it is questionable why the $354m funding was awarded, seemingly without competition, […]
Read more

Novavax receives $1.6bn from OWS with ambitious vaccine delivery target, says GlobalData

Following the news that US biotech Novavax announced it will receive $1.6bn funding for the development of its COVID-19 vaccine candidate NVX-CoV2373; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “Even with the Operation Warp Speed’s (OWS’s) support boosting Novavax’s late-stage clinical trials, manufacturing and […]
Read more

Hodgkin lymphoma diagnosed incident cases set to reach 27,000 in 2029

The burden of diagnosed Hodgkin lymphoma (HL) is expected to increase at an annual growth rate (AGR) of 0.90% from around 25,000 cases in 2019 to 27,000 cases in 2029 in the eight major markets (8MM*), according to GlobalData, a leading data and analytics company. GlobalData’s latest report: ‘Hodgkin Lymphoma: Epidemiology Forecast to 2029’ reveals […]
Read more

Dr Reddy’s takes lead in COVID-19 treatment with both favipiravir and remdesivir in portfolio, says GlobalData

Following the news that Indian pharmaceutical giant Dr. Reddy’s Laboratories (Dr Reddy’s) has signed tripartite agreement with Tokyo-based FUJIFILM Toyama Chemical and Dubai-based Global Response Aid (GRA) for the development, manufacturing and sales of favipiravir innovator brand Avigan; Anupama Mishra, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “This is […]
Read more

Long-term complications for COVID-19 patients could place a strain on the healthcare system, says GlobalData

Long-term complications arising in COVID-19 patients after recovering from the initial illness are expected to increase healthcare costs in the long-term. Complications such as stroke, intensive care unit delirium, post-traumatic stress disorder (PTSD), lung and heart damage and neurological issues may see a rise, as well as the development of long-term lung damage and fibrosis […]
Read more

Zeposia could help solve the unmet need of more oral drugs for moderate to severe CD and UC patients, says GlobalData

Following Bristol Myers Squibb’s positive topline results from its pivotal Phase III TRUE NORTH trial, it is possible that oral sphingosine1‐phosphate (S1P) Zeposia could have an impact on the treatment paradigm for ulcerative colitis (UC) due to its oral route of administration. If priced competitively, the drug could be used before biologic therapy, says GlobalData, […]
Read more

Big bio/pharma companies sales bolstered by COVID-19, says GlobalData

The COVID-19 pandemic has led to temporarily increased drug sales for biggest bio/pharma companies in the first quarter (Q1) of 2020. This increase over sales forecasts for Q1 2020 was due to COVID-19-related purchases, as people stockpiled in preparation for reduced medical access in the lockdown, says GlobalData, a leading data and analytics company. Madeleine […]
Read more

FDA’s Emergency Use Authorization benchmarks for COVID-19 vaccines remain ill-defined despite announcing approval requirements, says GlobalData

Following the US FDA’s issuance of its guidance document; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “The US Food and Drug Administration’s (FDA’s) vaccine guidance mirrors the World Health Organization’s (WHO’s) prior statement on minimal prerequisites for approval, including at least 50% protection, but the US agency’s comments […]
Read more

Adenovirus-vectored vaccines for COVID-19 could face booster issues

The usefulness of adenovirus-vectored vaccines for COVID-19 is currently questionable as these should only be administered two times over the lifetime of an individual and those currently in development only last for a year, says GlobalData, a leading data and analytics company. Johanna Swanson, Product Manager at GlobalData, comments: “Repeated administration of adenovirus-vectored vaccines can […]
Read more

Immunity passports may not be viable since COVID-19 antibodies last two to three months

The short duration of the COVID-19 antibodies throws into doubt the concept of immunity passports for this illness, as those who caught the disease could potentially catch it again. This is especially true if they were asymptomatic the first time around, as those patients had a shorter duration of antibodies, says GlobalData, a leading data and analytics company. Dara Lo, Medical Devices […]
Read more
1 … 88 89 90 91 92 … 111